04:20 PM EDT, 07/30/2026 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) reported Q2 adjusted earnings late Thursday of $2.85 per diluted share, up from $1.65 a year earlier.

Analysts polled by FactSet expected $2.17.

Revenue for the three months ended June 30 was $959 million, up from $688 million a year earlier.

Analysts surveyed by FactSet expected $891.2 million.